Related Experiment Videos
Mycoplasma pneumoniae protein involved in the antibody response in human infection
Abstract:
Antigen from purified Mycoplasma pneumoniae organisms treated with Tween-80-ether was used in a solid phase enzyme immunoassay and compared with the conventional lipid containing complement fixation antigen for measuring antibodies in sera from patients with aseptic or bacterial meningitis or with apparent M pneumoniae infection. In immunoblotting of the enzyme immunoassay antigen, enzyme immunoassay positive sera detected a polypeptide at Mr = 180.000-200.000, while enzyme immunoassay negative sera whether positive or negative in the complement fixation test did not. These results indicate that the enzyme immunoassay antigen containing the high molecular weight polypeptide can be used to measure M pneumoniae antibodies more specifically than the conventional lipid containing complement fixation antigen.
Insights
A new enzyme immunoassay using Mycoplasma pneumoniae antigen detected specific antibodies. This method, identifying a high molecular weight polypeptide, offers greater accuracy than traditional complement fixation tests for M. pneumoniae infections.
Area of Science:
- Immunology
- Microbiology
- Infectious Diseases
Background:
- Mycoplasma pneumoniae is a significant cause of respiratory infections and meningitis.
- Accurate serological diagnosis of M. pneumoniae infections is crucial for effective treatment.
- Conventional diagnostic methods, like complement fixation tests, may lack specificity.
Purpose of the Study:
- To develop and evaluate a novel solid-phase enzyme immunoassay (EIA) for detecting Mycoplasma pneumoniae antibodies.
- To compare the specificity and performance of the EIA using a purified M. pneumoniae antigen against a conventional complement fixation test (CFT) antigen.
- To identify specific antigenic components recognized by EIA-positive sera.
Main Methods:
- Purified Mycoplasma pneumoniae organisms were treated with Tween-80-ether to create an EIA antigen.
- The EIA antigen was used to measure antibodies in sera from patients with meningitis or M. pneumoniae infection.
- Immunoblotting was performed on the EIA antigen to identify reactive polypeptides.
- EIA results were compared with CFT results for the same patient sera.
Main Results:
- The EIA antigen detected antibodies in sera from patients with M. pneumoniae infection and some meningitis cases.
- Immunoblotting revealed that EIA-positive sera recognized a specific polypeptide with a molecular weight of 180,000-200,000.
- EIA-negative sera, regardless of CFT status, did not react with this polypeptide.
- The EIA demonstrated higher specificity in detecting M. pneumoniae antibodies compared to the CFT.
Conclusions:
- The developed enzyme immunoassay antigen, containing a high molecular weight polypeptide, is a more specific tool for measuring Mycoplasma pneumoniae antibodies.
- This EIA offers improved diagnostic accuracy for M. pneumoniae infections, particularly in differentiating from other causes of meningitis.
- The identification of the 180,000-200,000 molecular weight polypeptide provides a target for more specific serological assays.